{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Day - 1 (day before first IV infusion at each course) in the evening:', '-', 'H1 antagonist according to the local label (eg, cetirizine),', '-', 'H2 antagonist according to the local label (eg, ranitidine).', 'On days of IV infusions (1 hour prior to infusion):', '-', 'H2 antagonist: eg, ranitidine or equivalent,', '-', 'NSAID/antipyretic: paracetamol or equivalent,', '-', 'H1 antagonist IV diphenhydramine (25 mg or appropriate weight based dosing based', 'on local health authority recommendations [Appendix H]), immediately followed by:', '-', 'IV methylprednisolone: administer 1000 mg on infusion Days 1, 2, 3 (all courses) and', '>500 mg on infusion Days 4 and 5 (if 5 days of infusion).', 'Notes:', 'a) If diphenhydramine IV is not available, an equivalent H1 antagonist can be used at an equivalent dosing, via IV route,', 'b) If no H1 antagonist is available in IV formulation, an oral formulation of an', 'equivalent compound can be used at an equivalent dosing, 2 hours prior to infusion.', 'Day 4 and Day 5 of the first course:', '-', 'H1 antagonist, H2 antagonist, and antipyretics as needed,', '-', 'Fluid intake will be encouraged.', 'B) Concomitant medications:', 'Acyclovir 200 mg oral twice daily (or therapeutic equivalent) will also be provided/given', 'at the beginning on the first day of each treatment course and continuing for a minimum of', '1 month following treatment with alemtuzumab.', '8.3', 'BLINDING PROCEDURES', '8.3.1 Methods of blinding', 'This study has an open-label design. All enrolled patients will be on prior DMT when entering', 'into the study and will be treated with alemtuzumab during alemtuzumab treatment phase. No', 'randomization will be done.', 'The study will be rater-blinded for MRI. All brain scans will be reviewed and interpreted by one', 'or more MRI experts at an independent, central facility with no access (ie, blinded) to treatment', 'thereby avoiding bias. Refer to Section 9.1.1.1 and Section 9.2.1.1.', 'The MRI assessments will be available to the investigators to assess safety.', 'Property of the Sanofi Group - strictly confidential', 'Page 48', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '8.4', 'METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP', 'All enrolled patients will be on prior DMT when entering into the study and up to approximately', '4 months. After this period all patients will stop their prior DMT and will be treated with', 'alemtuzumab during alemtuzumab treatment phase.', 'No randomization will be performed.', 'An interactive voice response system (IVRS)/interactive web response system (IWRS) will be', 'used for this study to manage and control alemtuzumab dispensation. The treatment kit number', 'list is generated centrally by Sanofi. Alemtuzumab will be packaged in accordance with this list.', '8.5', 'PACKAGING AND LABELING', 'Packaging will be in accordance with the administration schedule. The content of the labeling will', 'be in accordance with the local regulatory specifications and requirements.', '8.6', 'STORAGE CONDITIONS AND SHELF LIFE', 'Investigators or other authorized persons (eg, pharmacists) are responsible for storing', 'alemtuzumab in a secure and safe place in accordance with local regulations, labeling', 'specifications, policies and procedures.', 'Control of storage conditions for alemtuzumab will be provided by the Sponsor, especially control', 'of temperature (eg, refrigerated storage) and information on in-use stability and instructions for', 'handling alemtuzumab.', 'Alemtuzumab, in vials, must be stored between +2\u00b0C to + 8\u00b0C (+36\u00b0F to +46\u00b0F). Do not freeze', 'and do not shake. Do not use alemtuzumab beyond the use by date provided on the label or other', 'documentation. Protect from light.', 'Prior to administration, protect diluted alemtuzumab solution from light and store for as long as', '8 hours either at room temperature 15\u00b0C to 25\u00b0C (59\u00b0F to 77\u00b0F) or keep refrigerated at conditions', '2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). From a microbiological point of view, it is recommended that the', 'product should be used immediately. Partially used, unused or damaged drug vials should be', 'disposed according to institutional policies.', 'Alemtuzumab will be used in accordance with the approved protocol and must not be used for any', 'other purpose.', '8.7 RESPONSIBILITIES', 'The Investigator, the hospital pharmacist, or other personnel allowed to store and dispense the', 'IMP will be responsible for ensuring that the IMP used in the clinical trial is securely maintained', 'as specified by the Sponsor and in accordance with applicable regulatory requirements.', 'Property of the Sanofi Group - strictly confidential', 'Page 49', 'VV-CLIN-02544065.0']\n\n###\n\n", "completion": "END"}